查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717199

阿兹海默症诊断与治疗市场（按产品、患者族群、疾病阶段、最终用户和分销管道）—2025-2030 年全球预测

Alzheimer's Disease Diagnostics & Therapeutics Market by Product, Patient Demographics, Disease Stage, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年阿兹海默症诊断和治疗市场价值为 71.5 亿美元，预计 2025 年将成长至 77.3 亿美元，复合年增长率为 8.50%，预计到 2030 年将达到 116.6 亿美元。

介绍

主要市场统计数据
基准年2024年 71.5亿美元
预计2025年 77.3亿美元
预测年份 2030 116.6亿美元
复合年增长率（%） 8.50%

阿兹海默症持续对全球医疗保健构成重大挑战，迫切需要创新的诊断和治疗解决方案。在技​​术快速进步和对神经退化性疾病更深入了解的推动下，市场正在经历重新定义临床和研究轨蹟的变革。本报告全面介绍了推动诊断和治疗突破性发展的新兴趋势、基于证据的见解和潜在的市场动态。当相关人员寻求平衡传统方法与颠覆性创新时，了解科学发现与市场现实之间的策略相互作用至关重要。以下讨论旨在为决策者提供一个细緻的视角，了解疾病检测和管理中不断发展的观点如何为更个性化、高效和有影响力的患者照护奠定基础。

透过整合最新的研究和市场分析，这项研究揭示了阿兹海默症治疗的多层面，同时确定了有望重塑竞争格局的关键机会。这是一个探索技术、生物学和策略洞察力融合的邀请，在这个市场中，每项进步都有可能显着改善患者的治疗效果。

改变阿兹海默症诊断和药物市场

阿兹海默症市场正在经历变革时期彻底改变诊断和治疗性介入的变革。科学突破加上不断发展的法律规范加速了新型生物标记和影像技术的应用，使得诊断能够在更早、更易于治疗的阶段检测出疾病。同时，研究资金的激增以及研究机构之间的合作也促进了有前景的治疗方案的出现。这些新治疗方法不仅基于基因洞察，还利用基因编辑和细胞疗法等先进的治疗方法重新定义治疗范式。

对研究重点进行策略性重新思考，加上提高对阿兹海默症社会影响的认识，将确保创新与以患者为中心的目标一致。同时，随着资料收集和分析技术的进步推动精准医疗的发展，病患的人口结构也在改变。这种快速发展的环境要求市场相关人员必须适应，在严格的临床检验需求和满足不断增长的患者期望需求之间取得平衡。随着诊断和治疗之间的界限变得越来越模糊，综合护理模式正在出现，提供从早期检测到有针对性的治疗计划的无缝过渡。

此外，数位健康和​​远端监控的进步正在重塑患者管理，使临床医生能够即时追踪病情进展。这些转变促使人们重新评估传统的市场结构，并开启跨学科创新与合作的时代。这一转变的背后通用，即透过及时干预、客製化治疗策略和强大的尖端解决方案来减轻阿兹海默症的负担，这将决定神经退化性疾病管理的未来。

关键环节分析

阿兹海默症诊断和治疗市场正变得越来越细緻入微，需要采用多方面的细分策略来深入了解机会和挑战。在产品层面，诊断用药和治疗用药划分明确。诊断技术已经发展到涵盖一系列工具，包括生物标记、认知评估测试、基因检测和先进的影像技术。具体来说，生物标记评估正在扩展到基于血液和基于脑脊髓液（CSF）的领域，为早期检测和疾病进展监测提供了双重方法。在治疗方面，市场分为新兴治疗和成熟的药物治疗。新兴疗法以基因疗法、单株抗体和干细胞疗法等创新疗法为主导，而传统药理学方法则以胆碱酯酶抑制剂和 NMDA 受体拮抗剂为基础。

透过将市场细分为反映发病率和治疗反应差异的年龄亚组，分析患者的人口统计数据可以提供进一步的见解。这包括对 65-74 岁、75-84 岁和 85 岁以上人群与 65 岁以下年轻群体进行比较的分析考虑。这些差异凸显了根据不同年龄组固有的生理和代谢变化来制定治疗方案的必要性。同时，分析疾病的阶段至关重要，早期、中期和晚期阿兹海默症患者之间存在显着差异。这种细分不仅为临床决策提供信息，而且还为根据疾病的病理学进展进行微调的有针对性的干预策略铺平了道路。

此外，按最终用户进行细分可以揭示诊断和治疗解决方案所部署的不同业务环境。家庭医疗保健机构正致力于整合远端患者监护并让居家照护护理人员参与其中，而医院和诊所则正在适应专门的老年病中心和神经科业务。包括学术和商业实验室在内的研究机构继续充当推动下一代临床突破的创新中心。此外，还绘製了医院、网路药局和零售药局的分销管道，展示了不断变化的患者偏好以及数位平台在药品分销中日益增长的作用。每一层细分都构成了整体情况，其特点是快速发展和适应性策略，以应对当前和未来的挑战。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球老化人口中阿兹海默症的盛行率不断上升
      • 引入基于生物标记的测试，以促进更早、更准确的诊断
      • 数位健康解决方案和穿戴式科技在阿兹海默症患者照护中的重要性日益增加
    • 限制因素
      • 开发和核准阿兹海默症药物的成本高昂
    • 机会
      • 专门管理和支持阿兹海默症患者的居家照护服务的增长
      • 加大研发投入推动阿兹海默症治疗取得新进展
    • 任务
      • 诊断标准缺乏标准化，导致阿兹海默症的诊断结果不一致。
  • 市场区隔分析
    • 产品：在阿兹海默症诊断中优先考虑血液生物标记物，有望实现广泛的筛检，而无需复杂的程序
    • 最终用户：在老年中心采用阿兹海默症症治疗和治疗方法来满足老年患者的复杂需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章阿兹海默症诊断与治疗市场（按产品）

  • 诊断
    • 生物标誌物
      • 血液中的生物标记
      • 脑脊髓液生物标记
    • 认知评估测试
    • 基因检测
    • 影像技术
  • 治疗
    • 新兴疗法
      • 基因治疗
      • 单株抗体
      • 干细胞疗法
    • 药物治疗
      • 胆碱酯酶抑制剂
      • NMDA受体拮抗剂

第七章阿兹海默症诊断与治疗市场（按患者人口统计）

  • 65-74岁
  • 75-84岁
  • 85岁或以上
  • 65岁以下

第八章阿兹海默症诊断和治疗药物市场（按疾病阶段）

  • 早期阿兹海默症
  • 晚期阿兹海默症
  • 中期阿兹海默症

第九章阿兹海默症诊断和治疗药物市场（按最终用户）

  • 家庭医疗保健
    • 家庭护理服务提供者
    • 远端患者监护
  • 医院和诊所
    • 老人中心
    • 神经科
  • 研究机构
    • 学术研究所
    • 私人研究机构

第 10 章阿兹海默症诊断和治疗药物市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

11.美国阿兹海默阿兹海默症诊断与治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12.亚太地区阿兹海默症诊断与药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13.欧洲、中东和非洲阿兹海默症诊断和治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbvie Inc.
  • AC Immune SA
  • Alector, Inc.
  • Alzheon, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • BioXcel Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • Cognoptix Inc.
  • Corium Inc.
  • Denali Therapeutics Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Grifols, SA
  • H. Lundbeck A/S
  • Lexeo Therapeutics, Inc.
  • Luye Pharma Group
  • Merz Pharma GmbH & Co. KGaA
  • MODAG GmbH
  • Muna Therapeutics
  • Novartis AG
  • Pfizer, Inc.
  • Siemens Healthineers AG
  • TauRx Therapeutics Ltd.
  • VectorY Therapeutics
  • Vigil Neuroscience, Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-742BD517AA98

The Alzheimer's Disease Diagnostics & Therapeutics Market was valued at USD 7.15 billion in 2024 and is projected to grow to USD 7.73 billion in 2025, with a CAGR of 8.50%, reaching USD 11.66 billion by 2030.

Introduction

KEY MARKET STATISTICS
Base Year [2024] USD 7.15 billion
Estimated Year [2025] USD 7.73 billion
Forecast Year [2030] USD 11.66 billion
CAGR (%) 8.50%

Alzheimer's disease continues to pose profound challenges across global healthcare landscapes, driving an urgent need for innovative diagnostic and therapeutic solutions. In an era marked by rapid technological advances and a deeper understanding of neurodegenerative conditions, the market is witnessing an evolution that redefines both clinical practice and research trajectories. This report provides a comprehensive exploration of emerging trends, evidence-based insights, and the underlying market dynamics fueling groundbreaking developments in diagnostics and therapeutics. As stakeholders seek to balance traditional methodologies with disruptive innovations, it becomes essential to appreciate the strategic interplay between scientific discovery and market realities. The following discussion aims to furnish decision-makers with a nuanced perspective on how evolving paradigms in disease detection and management are setting the stage for more personalized, efficient, and impactful patient care.

By integrating the latest research with market analytics, this analysis unfolds the multifaceted layers of Alzheimer's disease interventions while identifying key opportunities that promise to reshape the competitive landscape. It is an invitation to explore the confluence of technology, biology, and strategic insight in a market where every advancement holds the potential to significantly improve patient outcomes.

Transformative Shifts in the Landscape

The Alzheimer's disease market is undergoing transformative shifts that are revolutionizing diagnostic practices and therapeutic interventions. A confluence of scientific breakthroughs and evolving regulatory frameworks has accelerated the introduction of novel biomarkers and imaging technologies, positioning diagnostics to detect the disease at earlier and more treatable stages. Concurrently, a surge in research funding and cross-institutional collaborations has fortified the pipeline of promising therapeutic options. These emerging therapies are not only built on a foundation of genetic insights but are also leveraging advanced modalities such as gene editing and cellular therapies to redefine treatment paradigms.

The strategic reframing of research priorities, coupled with enhanced awareness of the societal impact of Alzheimer's, ensures that innovations are aligned with patient-centric goals. In parallel, the dynamics of patient demographics are shifting, supported by improvements in data acquisition and analytics that facilitate precision medicine. This rapidly evolving environment demands adaptability from market players, as they balance the need for rigorous clinical validation with the imperative to meet escalating patient expectations. As the lines between diagnostics and therapeutics increasingly blur, integrated care models are emerging that offer seamless transitions from early detection to targeted treatment plans.

Moreover, advancements in digital health and remote monitoring are reshaping patient management, allowing clinicians to track disease progression in real-time. These shifts are now prompting a reevaluation of traditional market structures, sparking an era of interdisciplinary innovation and collaboration. Underpinning these changes is a shared commitment to reducing the burden of Alzheimer's disease through timely intervention, customized treatment strategies, and a robust pipeline of cutting-edge solutions that are set to define the future of neurodegenerative disease management.

Key Segmentation Insights

The market for Alzheimer's diagnostics and therapeutics has become increasingly nuanced, driven by multi-dimensional segmentation strategies that provide a granular understanding of opportunities and challenges. At the product level, the landscape has been distinctly divided between diagnostics and therapeutics. Diagnostics have evolved to encompass a range of tools including biomarkers, cognitive assessment tests, genetic testing, and advanced imaging techniques. In particular, biomarker assessment now extends into both blood-based and cerebrospinal fluid (CSF) domains, offering a dual approach to early detection and disease progression monitoring. On the therapeutics side, market stratification distinguishes between emerging therapeutics and established pharmacological treatments. Emerging therapies are spearheaded by innovations such as gene therapy, monoclonal antibodies, and stem cell therapy, while traditional pharmacological approaches continue to be anchored by cholinesterase inhibitors and NMDA receptor antagonists.

Insights extend further when analyzing patient demographics, which segment the market into age subgroups that reflect variations in incidence and treatment responsiveness. These include analytical considerations for individuals aged 65-74 years, 75-84 years, and above 85 years, as compared to younger cohorts under 65. Such distinctions underscore the need for treatments that are tailored to the physiological and metabolic variations intrinsic to different age groups. In parallel, analyzing the disease stage is pivotal, with significant differences noted among patients in early-stage, middle-stage, and late-stage Alzheimer's. This segmentation not only informs clinical decision-making but also paves the way for creating targeted intervention strategies that can be fine-tuned based on the pathophysiological progression of the disease.

Furthermore, segmentation by end user reveals the diverse operational environments where diagnostic and therapeutic solutions are deployed. Home healthcare settings have garnered attention through the integration of remote patient monitoring and the involvement of home care providers, while hospitals and clinics adapt their operations within specialized geriatric centers and neurology departments. Research institutes, encompassing both academic and private laboratories, continue to serve as innovation hubs that drive the next generation of clinical breakthroughs. Additionally, distribution channels have been mapped out across hospital, online, and retail pharmacies, indicating evolving patient preferences and the growing role of digital platforms in medication distribution. Each layer of segmentation contributes to a holistic picture of a market characterized by rapid evolution and adaptive strategies aimed at meeting both current and future challenges.

Based on Product, market is studied across Diagnostics and Therapeutics. The Diagnostics is further studied across Biomarkers, Cognitive Assessment Tests, Genetic Testing, and Imaging Techniques. The Biomarkers is further studied across Blood-Based Biomarkers and CSF Biomarkers. The Therapeutics is further studied across Emerging Therapeutics and Pharmacological Treatments. The Emerging Therapeutics is further studied across Gene Therapy, Monoclonal Antibodies, and Stem Cell Therapy. The Pharmacological Treatments is further studied across Cholinesterase Inhibitors and NMDA Receptor Antagonists.

Based on Patient Demographics, market is studied across 65-74 Years, 75-84 Years, Above 85 Years, and Below 65 Years.

Based on Disease Stage, market is studied across Early-Stage Alzheimer's, Late-Stage Alzheimer's, and Middle-Stage Alzheimer's.

Based on End User, market is studied across Home Healthcare, Hospitals & Clinics, and Research Institutes. The Home Healthcare is further studied across Home Care Providers and Remote Patient Monitoring. The Hospitals & Clinics is further studied across Geriatric Centers and Neurology Departments. The Research Institutes is further studied across Academic Research Institutes and Private Research Laboratories.

Based on Distribution Channel, market is studied across Hospital pharmacies, Online pharmacies, and Retail pharmacies.

Key Regional Insights

Geographical segmentation reveals that the market dynamics for Alzheimer's disease diagnostics and therapeutics vary considerably across regions. In the Americas, robust research infrastructures, combined with substantial government and private funding, are fueling innovations in both early diagnosis and personalized treatment approaches. The region's strong emphasis on preventive care and integrated health management provides a solid foundation for the adoption of advanced diagnostic tools.

In Europe, the Middle East, and Africa, a unique blend of regulatory environments and patient demographics is driving tailored strategies. European markets exhibit a high level of clinical collaboration and regulatory support, while emerging economies in the Middle East and Africa are rapidly adapting to newer technologies through strategic public-private partnerships. The interplay of extensive healthcare networks and innovative clinical trial initiatives in these regions is fostering a competitive spirit that challenges conventional treatment paradigms.

Asia-Pacific presents a dynamic and rapidly growing landscape. Characterized by significant investment in healthcare technology and a rising prevalence of neurodegenerative disorders, this region is at the forefront of embracing digital health solutions. The convergence of technological adoption, rising healthcare expenditure, and proactive government initiatives are contributing to an environment of accelerated growth and innovation. This regional heterogeneity underscores the importance of localized strategies that can effectively balance global best practices with the nuanced needs of distinct demographic and economic contexts.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

A host of pioneering companies are actively reshaping the Alzheimer's diagnostics and therapeutics arena through a blend of strategic investments, innovative research, and robust market positioning. Industry leaders such as Abbvie Inc. and AC Immune SA have consistently demonstrated a commitment to advancing both diagnostic tools and therapeutic solutions, leveraging state-of-the-art technologies and expansive clinical networks. Companies like Alector, Inc. and Alzheon, Inc. have carved out distinctive niches by focusing on targeted molecular pathways, whereas firms such as Amylyx Pharmaceuticals, Inc. and AstraZeneca PLC are accelerating initiatives that encompass both early detection and intervention strategies.

This competitive milieu is further enriched by the contributions of organizations like Biogen Inc. and BioXcel Therapeutics Inc., which are successfully bridging the gap between laboratory research and clinical application. Established pharmaceutical giants like Bristol-Myers Squibb Company and Pfizer, Inc. are also central to this evolving narrative, investing heavily in both innovative therapeutics and comprehensive care models. Cognoptix Inc. and Corium Inc. further complement this diverse portfolio by introducing breakthrough diagnostic technologies. Additionally, companies such as Denali Therapeutics Inc. and Eisai Co., Ltd. are steadily advancing novel approaches that span early-stage diagnosis to the management of advanced symptoms.

Other notable contributors include Eli Lilly and Company, F. Hoffmann-La Roche AG, and Grifols, S.A., all of which are leveraging their global reach and technological prowess. H. Lundbeck A/S and Lexeo Therapeutics, Inc. are emerging leaders that underscore the role of niche strategies in a competitive landscape. The involvement of firms like Luye Pharma Group and Merz Pharma GmbH & Co. KGaA demonstrates a commitment to diversified product portfolios, while emerging entities such as MODAG GmbH and Muna Therapeutics continue to push the technological envelope. Companies including Novartis AG, Siemens Healthineers AG, TauRx Therapeutics Ltd., VectorY Therapeutics, Vigil Neuroscience, Inc., Voyager Therapeutics, Inc., and Zydus Lifesciences Limited together complete a vibrant ecosystem defined by relentless innovation and strategic foresight. Collectively, these organizations illustrate a dynamic blend of forward-thinking research, market adaptability, and a shared objective of mitigating the impact of Alzheimer's disease on global populations.

The report delves into recent significant developments in the Alzheimer's Disease Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., AC Immune SA, Alector, Inc., Alzheon, Inc., Amylyx Pharmaceuticals, Inc., AstraZeneca PLC, Biogen Inc., BioXcel Therapeutics Inc., Bristol-Myers Squibb Company, Cognoptix Inc., Corium Inc., Denali Therapeutics Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Grifols, S.A., H. Lundbeck A/S, Lexeo Therapeutics, Inc., Luye Pharma Group, Merz Pharma GmbH & Co. KGaA, MODAG GmbH, Muna Therapeutics, Novartis AG, Pfizer, Inc., Siemens Healthineers AG, TauRx Therapeutics Ltd., VectorY Therapeutics, Vigil Neuroscience, Inc., Voyager Therapeutics, Inc., and Zydus Lifesciences Limited. Actionable Recommendations for Industry Leaders

Industry leaders are advised to continuously monitor emerging trends and integrate flexible, adaptive strategies into their operational frameworks. Maintaining a forward-leaning perspective by investing in collaborative research ventures and advanced clinical trials is crucial. Profiles of traditional and innovative therapeutic solutions must coexist with a strong emphasis on real-world efficacy and patient-centric outcomes. Decision-makers should broaden their approaches by embracing digital health technologies, which not only drive cost efficiencies but also bolster patient management through remote monitoring and data analytics.

Strategic realignment toward personalized diagnostic platforms that utilize advanced biomarkers, genetic testing, and neuroimaging is essential to ensuring early disease detection and effective care planning. It is recommended that companies develop robust partnerships with academic research institutes and clinical centers to foster a more agile and responsive innovation ecosystem. Additionally, aligning product development with regulatory trends while anticipating changes in reimbursement policies will bolster market resilience.

Expanded investment in comprehensive patient segmentation studies can help tailor treatment modalities to distinct demographic and disease-stage profiles. This data-driven approach will empower market players to refine their portfolio strategies and optimize resource allocation. A commitment to leveraging local market insights, particularly across diverse regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific, will be a key driver in crafting region-specific strategies that capture both established opportunities and emerging niches. Embracing these recommendations will position industry leaders to not only navigate the current market volatility but also to sustainably drive future growth and innovation.

Conclusion

In summary, the Alzheimer's disease diagnostics and therapeutics landscape is marked by rapid innovation, evolving regulatory frameworks, and a diverse ecosystem of market players. The convergence of advanced diagnostic methodologies and cutting-edge therapeutic approaches presents a robust pathway for early detection and effective intervention, ultimately leading to enhanced patient outcomes. By embracing strategic segmentation that captures product nuances, patient demographics, disease stages, operational settings, and distribution channels, stakeholders can unlock value across multiple facets of the market.

The analysis underscores a clear trend: the integration of sophisticated biomarker analyses, genetic research, and neuroimaging technologies is transforming traditional paradigms. With an emphasis on personalized treatment plans that are tailored to the specific needs of diverse patient populations, the industry is poised for continued growth and evolution. Regional insights further highlight the need for adaptive strategies that leverage the unique strengths of various geographic markets. As companies innovate and compete on the global stage, the commitment to high-quality research and rigorous clinical validation remains paramount.

Ultimately, the report serves as a strategic guide that offers clear direction for exploiting market opportunities and mitigating risks in a rapidly changing environment. The comprehensive insights provided here are designed to arm stakeholders with the knowledge necessary to shape a resilient and forward-thinking market strategy that not only addresses current challenges but also unlocks future potential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of Alzheimer's disease among the aging global population
      • 5.1.1.2. Introduction of biomarker-based tests facilitating early and accurate diagnosis
      • 5.1.1.3. Rising prominence of digital health solutions and wearable technology in Alzheimer's patient care
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with Alzheimer's disease drug development and approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Growth in home-based care services tailored for Alzheimer's patient management and support
      • 5.1.3.2. Increasing investments in research and development fuel new advancements in Alzheimer's therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardization in diagnostic criteria contributes to inconsistent Alzheimer's diagnosis results
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Preference for blood based biomarker for alzheimer disease diagnostics to offer promise for widespread screening without the need for complex procedures
    • 5.2.2. End User: Adoption of Alzheimer disease treatment & therapeutics in geriatric centers to manage the complex needs of elderly patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alzheimer's Disease Diagnostics & Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnostics
    • 6.2.1. Biomarkers
      • 6.2.1.1. Blood-Based Biomarkers
      • 6.2.1.2. CSF Biomarkers
    • 6.2.2. Cognitive Assessment Tests
    • 6.2.3. Genetic Testing
    • 6.2.4. Imaging Techniques
  • 6.3. Therapeutics
    • 6.3.1. Emerging Therapeutics
      • 6.3.1.1. Gene Therapy
      • 6.3.1.2. Monoclonal Antibodies
      • 6.3.1.3. Stem Cell Therapy
    • 6.3.2. Pharmacological Treatments
      • 6.3.2.1. Cholinesterase Inhibitors
      • 6.3.2.2. NMDA Receptor Antagonists

7. Alzheimer's Disease Diagnostics & Therapeutics Market, by Patient Demographics

  • 7.1. Introduction
  • 7.2. 65-74 Years
  • 7.3. 75-84 Years
  • 7.4. Above 85 Years
  • 7.5. Below 65 Years

8. Alzheimer's Disease Diagnostics & Therapeutics Market, by Disease Stage

  • 8.1. Introduction
  • 8.2. Early-Stage Alzheimer's
  • 8.3. Late-Stage Alzheimer's
  • 8.4. Middle-Stage Alzheimer's

9. Alzheimer's Disease Diagnostics & Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Home Healthcare
    • 9.2.1. Home Care Providers
    • 9.2.2. Remote Patient Monitoring
  • 9.3. Hospitals & Clinics
    • 9.3.1. Geriatric Centers
    • 9.3.2. Neurology Departments
  • 9.4. Research Institutes
    • 9.4.1. Academic Research Institutes
    • 9.4.2. Private Research Laboratories

10. Alzheimer's Disease Diagnostics & Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital pharmacies
  • 10.3. Online pharmacies
  • 10.4. Retail pharmacies

11. Americas Alzheimer's Disease Diagnostics & Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Alzheimer's Disease Diagnostics & Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Alzheimer's Disease Diagnostics & Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. AbbVie acquires Aliada Therapeutics to enhance Alzheimer's Disease research and innovations
    • 14.3.2. Eisai invests in C2N to enhance early Alzheimer's Disease diagnosis and treatment
    • 14.3.3. IHI launches interdisciplinary initiative to transform Alzheimer's Disease diagnosis and treatment
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. AC Immune SA
  • 3. Alector, Inc.
  • 4. Alzheon, Inc.
  • 5. Amylyx Pharmaceuticals, Inc.
  • 6. AstraZeneca PLC
  • 7. Biogen Inc.
  • 8. BioXcel Therapeutics Inc.
  • 9. Bristol-Myers Squibb Company
  • 10. Cognoptix Inc.
  • 11. Corium Inc.
  • 12. Denali Therapeutics Inc.
  • 13. Eisai Co., Ltd.
  • 14. Eli Lilly and Company
  • 15. F. Hoffmann-La Roche AG
  • 16. Grifols, S.A.
  • 17. H. Lundbeck A/S
  • 18. Lexeo Therapeutics, Inc.
  • 19. Luye Pharma Group
  • 20. Merz Pharma GmbH & Co. KGaA
  • 21. MODAG GmbH
  • 22. Muna Therapeutics
  • 23. Novartis AG
  • 24. Pfizer, Inc.
  • 25. Siemens Healthineers AG
  • 26. TauRx Therapeutics Ltd.
  • 27. VectorY Therapeutics
  • 28. Vigil Neuroscience, Inc.
  • 29. Voyager Therapeutics, Inc.
  • 30. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD-BASED BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CSF BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE ASSESSMENT TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 75-84 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ABOVE 85 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BELOW 65 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LATE-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MIDDLE-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REMOTE PATIENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROLOGY DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 173. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 185. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 186. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 197. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 198. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 199. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 210. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 211. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 212. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 223. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 224. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 225. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 236. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 238. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 249. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 250. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 251. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 262. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNO